One dose vaccination with
View Patent ↗The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.
1. A method of treating or preventing a disease or disorder in an animal caused by infection with Mycoplasma hyopneumoniae (M. hyopneumoniae) comprising administering to the animal at from about 3 to about 10 days of age, an effective amount of a single dose of a Mycoplasma hyopneumoniae vaccine, wherein said M. hyopneumoniane vaccine comprises an inactivated M. hyopneumoniane whole cell preparation and wherein said single dose of the M. hyopneumoniane vaccine contains at least about 1×10 8 color changing units (CCU).
2. The method according to claim 1 wherein the animal is a pig.
3. The method according to claim 2 , wherein said swine is seropositive for Mycoplasma hyopneumoniae.
4. The method according of claim 2 , wherein said swine is seropositive for Mycoplasma hyopneumoniae.
5. The method according of claim 2 , wherein said swine are protected up to 25 weeks following vaccination.
6. The method of claim 1 , wherein the single dose of the M. hyopneumoniae vaccine contains from about 1×10 8 to 5×10 10 color changing units (CCU) per dose.
7. The method of claim 6 wherein the single dose of the M. hyopneumoniae vaccine contains from about 5×10 8 to 5×10 10 color changing units (CCU) per dose.
8. The method of claim 1 wherein the amount of said vaccine administered is from about 0.5 to about 3.0 ml.
9. The method of claim 1 wherein the amount of said vaccine administered is from about 1.5 ml to about 2.5 ml.
10. The method of claim 1 wherein the amount of said vaccine administered is about 2 ml.
11. The method of claim 1 wherein the Mycoplasma hyopneumoniae cell preparation is RESPISURE-1.
12. The method of claim 1 wherein the Mycoplasma hyopneumoniae vaccine further comprises a viral or bacterial antigen other than Mycoplasma hyopneumoniae.
13. The method of claim 12 wherein the said viral or bacterial antigens are selected from swine influenza virus (SIV), porcine reproductive and respiratory disease virus (PRRS or mystery swine disease), post-weaning diarrhea (PWD) and porcine proliferative enteritis (PPE).
14. The method according to claim 1 wherein said Mycoplasma hyopneumoniae preparation is administered intramuscularly.
15. The method according to claim 1 wherein the Mycoplasma hyopneumoniae vaccine further comprises an adjuvant.
16. The method according to claim 15 wherein the adjuvant is selected from the group consisting of: mineral gels; surface active substances such as lysolecityhin; glycosides comprising saponin or, saponin derivatives such as Quil A or GP1-0100; pluronic polyols; polyanions; non-ionic block polymers, mineral oils, oil emulsions, an emulsion of vegetable oil, water and an emulsifier such as lecithin; alum, cytokines, CpG oligonucleotides, and MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero- 3-hydroxyphosphoryloxy)-ethylamine; rmLT, and AMPHIGEN.
17. The method according to claim 1 wherein the Mycoplasma hyopneumoniae further comprises a pharmaceutically acceptable carrier.
18. A method of treating or preventing a disease or disorder in a pig caused by infection with Mycoplasma hyopneumoniae (M. hyopneumoniae) consisting essentially of administering to the pig at from about 3 to about 10 days of age, an effective amount of a single dose of an M. hyopneumoniae vaccine which induces protective immunity in both seropositive pigs and seronegative pigs, said M. hyopneumoniae vaccine comprising an inactivated M. hyopneumoniae whole cell preparation and wherein said single dose of the M. hyopneumoniae vaccine contains at least about 1×10 8 color changing units (CCU).
19. The method according to claim 18, wherein said pig is seropositive for Mycoplasma hyopneumoniae.
20. The method according to claim 18, wherein said pig is seronegative for Mycoplasma hyopneumoniae.
21. The method according to claim 18, wherein said pig is protected up to 25 weeks following vaccination.
22. The method of claim 18, wherein the single dose of the M. hyopneumoniae vaccine contains from about 1×10 8 to 5×10 10 color changing units (CCU) per dose.
23. The method of claim 22 wherein the single dose of the M. hyopneumoniae vaccine contains from about 5×10 8 to 5×10 10 color changing units (CCU) per dose.
24. The method of claim 18 wherein the amount of said vaccine administered is from about 0.5 to about 3.0 ml.
25. The method of claim 18 wherein the amount of said vaccine administered is from about 1.5 ml to about 2.5 ml.
26. The method of claim 18 wherein the amount of said vaccine administered is about 2 ml.
27. The method of claim 18 wherein the Mycoplasma hyopneumoniae cell preparation is RESPISURE-1.
28. The method of claim 18 wherein the Mycoplasma hyopneumoniae vaccine further comprises a viral or bacterial antigen other than Mycoplasma hyopneumoniae.
29. The method of claim 28 wherein the said viral or bacterial antigens are selected from swine influenza virus (SIV), porcine reproductive and respiratory disease virus (PRRS or mystery swine disease), post-weaning diarrhea (PWD) and porcine proliferative enteritis (PPE).
30. The method according to claim 18 wherein said Mycoplasma hyopneumoniae preparation is administered intramuscularly.
31. The method according to claim 18 wherein the Mycoplasma hyopneumoniae vaccine further comprises an adjuvant.
32. The method according to claim 31 wherein the adjuvant is selected from the group consisting of: mineral gels; surface active substances such as lysolecithin; glycosides comprising saponin or, saponin derivatives such as Quil A or GP1-0100; pluronic polyols; polyanions; non-ionic block polymers, mineral oils, oil emulsions, an emulsion of vegetable oil, water and an emulsifier such as lecithin; alum, cytokines, CpG oligonucleotides, and MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine; rmLT, and AMPHIGEN.
33. The method according to claim 18 wherein the Mycoplasma hyopneumoniae vaccine further comprises a pharmaceutically acceptable carrier.